Govt panel set to review if nutraceuticals should be brought under CDSCO

The nutraceutical market in India is estimated to reach $ 18 billion by the end of 2025 as compared to $ 4 billion in 2020, according to industry data

Nutraceuticals image via Shutterstock.
Press Trust of India New Delhi
3 min read Last Updated : Feb 18 2024 | 2:46 PM IST

The government has formed a panel to examine the possibility of bringing nutraceuticals under the ambit of the apex drug regulator CDSCO instead of the food regulator FSSAI to address regulatory challenges and promote consumer safety

Presently, the Food Safety and Standards Authority of India (FSSAI) regulates the usage of health supplements and nutraceuticals under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, and Prebiotic and Probiotic Food) Regulations, 2022.

This regulation covers food items that are specially processed or formulated for specific nutritional or dietary purposes, official sources said.

Nutraceuticals are products derived from food sources that are believed to provide extra health benefits besides the basic nutritional value found in foods

The sources said that the challenges in uniform implementation and enforcement, interchangeable usage of the same nutrient/ingredient at different doses for pharma and nutraceutical use and overlap in phylactic and therapeutic usage along with disease risk reduction claims were discussed with the Central Drugs Standard Control Organisation (CDSCO) officials in a recent meeting.

"Several issues were discussed following which a high-level committee under the chairmanship of Secretary, Ministry of Health has been constituted to review the regulatory challenges in nutraceutical and drugs to ensure consumer safety," a source said.

The committee has as its members Secretary, Ministry of Ayush, Secretary, Ministry of Food Processing Industries, Secretary, Department of Pharmaceuticals, Chief Executive Officer (CEO), FSSAI, Drugs Controller General of India, Director General, Indian Council of Medical Research and Director General of Health Services (DGHS) as members.

The nutraceutical market in India is estimated to reach $ 18 billion by the end of 2025 as compared to $ 4 billion in 2020, according to industry data.

During the meeting some officials noted that many health supplements like probiotics, vitamins, minerals and botanicals also have therapeutic usage and due to unclear demarcation, many companies are shifting from CDSCO to FSSAI for approval of ingredients which are akin to drugs such as melatonin and zinc carnosine.

Some officials said several supplements are marketed with disease management/disease risk reduction claims considering that the same ingredients are permitted in both drugs and nutra regulations, the sources stated.

"Besides, there is no mandatory medical supervision for products covered under nutra regulations as a result people might consume it for longer duration and/or in higher doses which might prove harmful," the sources said.

Officials said due to unsupervised usage of supplements, people at the same time consume supplements along with drugs which might interact with each other and may cause adverse effects on the health of the consumer.

Due to availability of health supplements over the counter there are chances of consuming multiple nutrients whose action might be antagonistic to each other like calcium from a multi-mineral supplement might affect the absorption of iron.

"The committee will identify the feasibility of regulating probiotic/prebiotic in food formats and drug formats. It will also examine if there is a need and possibility of bringing nutraceuticals and health supplements under the ambit of the CDSCO," another official source said.

The panel will also explore the feasibility of price control for categories covered under nutraceutical regulations, besides, examining the feasibility of GMP provisions and certification for nutraceuticals and similar products in alignment with schedule M of drugs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :NutraceuticalHealth MinistryCDSCOFSSAIFSSAI hygiene

First Published: Feb 18 2024 | 2:45 PM IST

Next Story